Clinical Trial Update: REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on remimazolam infusion for hypnotic management in acute respiratory failure during COVID-19, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Failure

Drugs mentioned

• Remimazolam (remimazolam)

Snippet

Sponsor: Nantes University Hospital | Conditions: Acute Respiratory Failure, COVID-19 | Phase 2 | Status: COMPLETED